Effectiveness and safety of rivaroxaban vs warfarin in patients with pulmonary embolism and right ventricular dysfunction: a retrospective cohort study

QR Code

Effectiveness and safety of rivaroxaban vs warfarin in patients with pulmonary embolism and right ventricular dysfunction: a retrospective cohort study

Background: Limited data exist comparing the effectiveness and safety of rivaroxaban and warfarin in patients with right ventricular dysfunction (RVD), a common acute pulmonary embolism (PE) complication. Objectives: To assess the effectiveness and safety of rivaroxaban compared with warfarin among...

Full description

Saved in:

Bibliographic Details
Main Authors:	François Laliberté, Behnood Bikdeli, Veronica Ashton, Guillaume Germain, Julien Boudreau, Manasvi Sundar, Sean D. MacKnight, Brahim Bookhart, Dereck Wentworth, Shawn Murphy, Yichuan G. Hsieh, Gregory Piazza
Format:	Article
Language:	English
Published:	Elsevier 2025-07-01
Series:	Research and Practice in Thrombosis and Haemostasis
Subjects:	pulmonary embolism right ventricular dysfunction rivaroxaban venous thromboembolism warfarin
Online Access:	http://www.sciencedirect.com/science/article/pii/S2475037925002754
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin
by: I. Yu. Koroleva, et al.
Published: (2016-11-01)

PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD
by: L. Y. Koroleva, et al.
Published: (2015-12-01)

PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD
by: L. Y. Koroleva, et al.
Published: (2015-09-01)

Elderly Patients with Atrial Fibrillation: Focus on Comorbidity and Safety of Anticoagulant Therapy
by: D. A. Napalkov, et al.
Published: (2019-09-01)

Pharmacogenetic substantiation of personalized prescription of oral anticoagulants in clinical practice
by: K.I. Bentsionova, et al.
Published: (2023-03-01)

ПРИМЕНЕНИЕ ПЕРОРАЛЬНЫХ АНТИКОАГУЛЯНТОВ ПРИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ: СОВРЕМЕННОЕ СОСТОЯНИЕ ПРОБЛЕМЫ И НОВЫЕ ВОЗМОЖНОСТИ
by: Г. И. Сторожаков, et al.
Published: (2013-04-01)

Clinical outcomes of direct oral anticoagulant off-label dosing in nonvalvular atrial fibrillation
by: M. Jansson, et al.
Published: (2025-09-01)

Anticoagulant Therapy in Difficult Patients with Atrial Fibrillation: When the Risks of Embolism and Bleeding Are Comparable
by: D. A. Napalkov, et al.
Published: (2018-11-01)

WARFARIN IN PATIENTS WITH CARDIOEMBOLIC STROKE
by: E. N. Dankovtseva, et al.
Published: (2015-12-01)

Bayer registered a new indication for rivaroxaban for use in patients with coronary heart disease or peripheral artery disease in the European Union and USA
by: Bayer Company Press Release
Published: (2018-11-01)

Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice
by: A. A. Zarudsky, et al.
Published: (2020-03-01)

Clinical Case: Atypical Warfarin-induced Skin Necrosis
by: T. V. Kondratieva, et al.
Published: (2019-11-01)

Application of <i>in vitro</i> studies to predict the pharmacokinetics of rivaroxaban tablets
by: A. V. Suvorova, et al.
Published: (2024-09-01)

RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION
by: M. Yu. Gilyarov
Published: (2015-12-01)

NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY
by: D. A. Napalkov, et al.
Published: (2015-09-01)

ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: A. V. Rudakova
Published: (2015-09-01)

NOVEL APPROACH TO ANTITHROMBOTIC TREATMENT OF ACUTE CORONARY PATIENTS WITH RIVAROXABAN
by: I. N. Bokarev, et al.
Published: (2015-07-01)

Diagnosis of Impairments in the Hemostatic System in the Use of Warfarin in Cardiac Surgical Patients
by: E. I. Goncharova, et al.
Published: (2015-09-01)

SYNTHESIS, PHYSICO-CHEMICAL ANALYSIS AND PHARMACOLOGICAL ACTIVITY OF SOME DERIVATIVES OF WARFARIN
by: A. Z. Abyshev, et al.
Published: (2019-01-01)

ANALYSIS OF DIRECT COSTS ASSOCIATED WITH THE USE OF WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION
by: Yu. B. Belousov, et al.
Published: (2016-01-01)

Changes in prescribing antithrombotic therapy in patients with atrial fibrillation and myocardial infarction in 2016-2019
by: K. G. Pereverzeva, et al.
Published: (2020-08-01)

Analysis of Anticoagulant Therapy in the Elderly Patients, in Clinical Practice of Family Medicine Centers in the Kyrgyz Republic
by: S. M. Mamatov, et al.
Published: (2021-05-01)

ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT
by: E. L. Dolgova, et al.
Published: (2015-09-01)

Nontraumatic warfarin-related intrapulmonary hemorrhage presenting as a lung mass
by: Hiroyuki Tsuchida, et al.
Published: (2020-04-01)

SAFETY OF LONGTERM THERAPY WITH WARFARIN: POSSIBILITY OF TREATMENT RENEWING AFTER HEMORRHAGIC COMPLICATIONS
by: E. S. Kropacheva
Published: (2016-01-01)

Latent opportunities for the prevention of ischemic stroke in patients with atherosclerosis-related diseases: additional analysis of randomized trials on rivaroxaban
by: S. R. Gilyarevskiy
Published: (2020-03-01)

THE INVASIVE DENTAL PROCEDURES IN PATIENTS TREATING WITH WARFARIN: POSSIBILITIES AND PROSPECTS FOR SAFETY
by: T. V. Kozlova, et al.
Published: (2016-01-01)

Pharmacogenetics and pharmacokinetics of rivaroxaban in patients with atrial fibrillation and chronic kidney disease
by: N. A. Shatalova, et al.
Published: (2023-11-01)

Scrotal variceal bleeding during rivaroxaban therapy as alarming sign in senescent patients: A clinical case
by: S. A. Chepurnenko, et al.
Published: (2022-06-01)

Application of rivaroxaban in clinical practice: results of a prospective observational study XANTUS in patients with atrial fibrillation
by: S. G. Kanorskii
Published: (2016-09-01)

CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: S. V. Nedogoda, et al.
Published: (2017-03-01)

Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review
by: B. A. Tatarsky, et al.
Published: (2019-11-01)

Possibilities of Using Rivaroxaban in Elderly Patients with Atrial Fibrillation: Data from Randomized Studies and Real Clinical Practice
by: N. M. Vorobyeva, et al.
Published: (2018-09-01)

Current approaches to periprocedural anticoagulation treatment in patients undergoing atrial fibrillation ablation
by: N. Z. Gasymova, et al.
Published: (2019-05-01)

ПАЦИЕНТ С МЕРЦАТЕЛЬНОЙ АРИТМИЕЙ НА АМБУЛАТОРНОМ ПРИЁМЕ У ТЕРАПЕВТА
by: А. Л. Вёрткин, et al.
Published: (2013-06-01)

Should a physician use the Beers criteria when prescribing direct oral anticoagulants to elderly patients?
by: N. M. Vorobyeva, et al.
Published: (2024-10-01)

Alternative therapy interaction with warfarin: what doctors should know
by: T. B. Kozlova, et al.
Published: (2010-06-01)

Single-Dose Bioequivalence Study of Rivaroxaban-Containing Medicinal Products in Healthy Volunteers
by: G. N. Gildeeva, et al.
Published: (2022-10-01)

APPLICATION OF RIVAROXABAN IN ACUTE CORONARY SYNDROME: EVIDENCE AND CURRENT GUIDELINES
by: O. V. Averkov
Published: (2016-01-01)

Combination therapy with methylprednisolone and rivaroxaban for mild COVID-19 in Vietnam: laboratory and clinical insights
by: Thu, Le Thi Anh, et al.
Published: (2025-07-01)